SEC Filing Analysis: ZIMMER BIOMET HOLDINGS, INC. (ZBH)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Executive VP & CFO, Suketu Upadhyay, was awarded 10,632 Restricted Stock Units (RSUs) after meeting pre-determined performance goals. This is a routine compensation event, not an open-market transaction.
• Market Impact: Neutral. The transaction is immaterial in size and represents a standard component of executive compensation with negligible impact on shareholder dilution.

Company Information

Field	Value
Company	ZIMMER BIOMET HOLDINGS, INC.
Ticker Symbol	ZBH
CIK	0001136869
Industry	Orthopedic, Prosthetic & Surgical Appliances & Supplies

Insider Information

Field	Value
Name	Upadhyay Suketu
CIK	0001533149
Title/Position	Exec VP, CFO
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-10-24
Transaction Code	A (Grant, award, or other acquisition)
Security Type	Restricted Stock Units
Shares Involved	10,632
Price Per Share	$0.00
Total Value	$0
Shares Owned After	10,632
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0
% of Market Cap	0.00%
Shares Transacted	10,632
% of Shares Outstanding	0.005%
Post-Transaction Ownership	10,632 shares (0.005% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a large-cap company with a market capitalization of $19.92 billion, this transaction is financially immaterial.
• Ownership Concentration: The CFO's direct holdings following this award remain a very small fraction of the total shares outstanding.
• Dilution Impact: The issuance of 10,632 shares represents a negligible dilution of approximately 0.005% to existing shareholders, which is a routine cost of executive compensation.
• Transaction Significance: The transaction's significance is low, as it is a non-cash, non-market compensation event representing a tiny fraction of the company's equity.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This is a scheduled compensation award based on past performance criteria. It does not reflect the insider's current sentiment or a new investment decision, and its size is insignificant relative to the company's market capitalization.

Volume & Sentiment

• Expected Volume Impact: None. This is a grant of equity and not an open-market transaction, so it will not directly impact trading volume.
• Sentiment Indicator: Neutral. The market typically views such routine executive compensation events as standard business practice.

Additional Context

Transaction Notes

• Special Circumstances: As per the filing's footnotes, these RSUs were earned from a performance-based grant made on September 1, 2023. The number of shares was determined on October 24, 2025, based on performance achieved. The earned RSUs are scheduled to vest on November 10, 2025.